Literature DB >> 8781143

Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity.

K Ito1, T Kato, T Ohta, M Tadokoro, T Yamada, M Ikeda, M Nishino, T Ishigaki, S Gambhir.   

Abstract

The aim of this study was to assess the value of fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography in patients with recurrent rectal cancer, in relation to tumour size and cellularity. Thirty-seven patients (21 mean and 16 women; mean age, 55.4+/-9.58 years) with suspected recurrence of rectal cancer were studied. FDG uptake was quantified by the differential absorption ratio (DAR). In 29 patients magnetic resonance imaging was also performed. To evaluate the signal intensity of the lesion, the lesion to muscle signal intensity ratios (SIR) were calculated on T2-weighted images. In seven patients who received surgical treatment the DAR and SIR were compared with the tumour cellularity. All 32 patients with confirmed recurrence showed increased FDG accumulation in the mass (DAR=4.57+/-1.89) in comparison with low FDG accumulation in five patients with scar (DAR=1.17+/-0.43). There was a significant correlation (r=0.661, P<0.001) between the DAR and the tumour diameter. There was no correlation between the DAR and SIR, whereas there was a significant correlation (r=0.565, P<0.01) between the DAR corrected using count recovery coefficient (DAR*) and SIR. In the histopathological findings there was a tendency for the DAR* and SIR to correlate with tumour cellularity. It is concluded that the DAR of recurrent rectal cancer should be evaluated taking into consideration the tumour size and cellularity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781143     DOI: 10.1007/bf01367594

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  21 in total

1.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study.

Authors:  K Kubota; T Matsuzawa; T Fujiwara; M Ito; J Hatazawa; K Ishiwata; R Iwata; T Ido
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

2.  Recurrence of colorectal tumors: PET evaluation.

Authors:  L G Strauss; J H Clorius; P Schlag; B Lehner; B Kimmig; R Engenhart; M Marin-Grez; F Helus; F Oberdorfer; P Schmidlin
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

3.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

4.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.

Authors:  N A Dewan; N C Gupta; L S Redepenning; J J Phalen; M P Frick
Journal:  Chest       Date:  1993-10       Impact factor: 9.410

5.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

6.  Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.

Authors:  R Bares; P Klever; D Hellwig; S Hauptmann; J Fass; U Hambuechen; L Zopp; B Mueller; U Buell; V Schumpelick
Journal:  Nucl Med Commun       Date:  1993-07       Impact factor: 1.690

7.  Recurrent rectal cancer and scar: differentiation with PET and MR imaging.

Authors:  K Ito; T Kato; M Tadokoro; T Ishiguchi; M Oshima; T Ishigaki; S Sakuma
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

8.  Noninvasive grading of musculoskeletal tumors using PET.

Authors:  L P Adler; H F Blair; J T Makley; R P Williams; M J Joyce; G Leisure; N al-Kaisi; F Miraldi
Journal:  J Nucl Med       Date:  1991-08       Impact factor: 10.057

9.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

10.  Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI.

Authors:  J W Braams; J Pruim; N J Freling; P G Nikkels; J L Roodenburg; G Boering; W Vaalburg; A Vermey
Journal:  J Nucl Med       Date:  1995-02       Impact factor: 10.057

View more
  9 in total

1.  Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Junichi Kodama; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

2.  Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.

Authors:  Manuel Rodríguez-Garrido; Cristina Asensio-del-Barrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

3.  Peritoneal recurrence of colon cancer detected by positron emission tomography: report of a case.

Authors:  S Yasuda; H Makuuchi; S Sadahiro; M Mukai; H Ishida; N Tokunaga; T Kimura; T Tajima; A Shohtsu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla.

Authors:  Julia Fruehwald-Pallamar; Christian Czerny; Marius E Mayerhoefer; Benjamin S Halpern; Christina Eder-Czembirek; Markus Brunner; Matthias Schuetz; Michael Weber; Laura Fruehwald; Andreas M Herneth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-05       Impact factor: 9.236

5.  The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Chikako Fukushima; Tomoko Haruma; Chiaki Hayashi; Tomoyuki Kusumoto; Noriko Seki; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

6.  Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.

Authors:  Kung-Chu Ho; Gigin Lin; Jiun-Jie Wang; Chyong-Huey Lai; Chee-Jen Chang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

7.  Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.

Authors:  Maren Marie Sjaastad Andreassen; Pål Erik Goa; Torill Eidhammer Sjøbakk; Roja Hedayati; Hans Petter Eikesdal; Callie Deng; Agnes Østlie; Steinar Lundgren; Tone Frost Bathen; Neil Peter Jerome
Journal:  MAGMA       Date:  2019-09-27       Impact factor: 2.310

8.  Correlation between Tissue Cellularity and Metabolism Represented by Diffusion-Weighted Imaging (DWI) and 18F-FDG PET/MRI in Head and Neck Cancer (HNC).

Authors:  Omar Freihat; Tóth Zoltán; Tamas Pinter; András Kedves; Dávid Sipos; Imre Repa; Árpád Kovács; Cselik Zsolt
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

9.  Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma.

Authors:  Bo Bae Choi; Sung Hun Kim; Bong Joo Kang; Ji Hye Lee; Byung Joo Song; Seung Hee Jeong; Hyeon Woo Yim
Journal:  World J Surg Oncol       Date:  2012-06-28       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.